DEA, finally, schedules Eisai's epilepsy drug Fycompa
This article was originally published in Scrip
Executive Summary
With the issuance of a final rule on 2 December, the Drug Enforcement Administration (DEA) placed Eisai’s epilepsy drug Fycompa (perampanel), including its salts, isomers and salts of isomers, into Schedule III of the Controlled Substances Act (CSA) – an action that did not come easily for the company.